Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists
- 29 March 2007
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 193 (2) , 159-170
- https://doi.org/10.1007/s00213-007-0766-3
Abstract
Rationale Identification of behaviors specifically mediated by the dopamine D2 and D3 receptors would allow for the determination of in vivo receptor selectivity and aide the development of novel therapeutics for dopamine-related diseases. Objectives These studies were aimed at evaluating the specific receptors involved in the mediation of D2/D3 agonist-induced yawning and hypothermia. Materials and methods The relative potencies of a series of D2-like agonists to produce yawning and hypothermia were determined. The ability of D3-selective and D2-selective antagonists to inhibit the induction of yawning and hypothermia were assessed and a series of D2/D3 antagonists were characterized with respect to their ability to alter yawning induced by a low and high dose of PD-128,907 and sumanirole-induced hypothermia. Results D3-preferring agonists induced yawning at lower doses than those required to induce hypothermia and the D2-preferring agonist, sumanirole, induced hypothermia at lower doses than were necessary to induce yawning. The rank order of D3 selectivity was pramipexole > PD-128,907 = 7-OH-DPAT = quinpirole = quinelorane > apomorphine = U91356A. Sumanirole had only D2 agonist effects. PG01037, SB-277011A, and U99194 were all D3-selective antagonists, whereas haloperidol and L-741,626 were D2-selective antagonists and nafadotride’s profile of action was more similar to the D2 antagonists than to the D3 antagonists. Conclusions D3 and D2 receptors have specific roles in the mediation of yawning and hypothermia, respectively, and the analysis of these effects allow inferences to be made regarding the selectivity of D2/D3 agonists and antagonists with respect to their actions at D2 and D3 receptors.Keywords
This publication has 55 references indexed in Scilit:
- 2-[(4-Phenylpiperazin-1-yl)methyl]imidazo(di)azines as Selective D4-Ligands. Induction of Penile Erection by 2-[4-(2-Methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a Potent and Selective D4Partial AgonistJournal of Medicinal Chemistry, 2006
- Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the ratInternational Journal of Neuropsychopharmacology, 2006
- Sumanirole, a Highly Dopamine D2-Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson’s DiseaseThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2high and D3high receptorsSynapse, 2005
- Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated BehaviorThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Design and Synthesis of trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2- yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A Potent and Selective Dopamine D3 Receptor Antagonist with High Oral Bioavailability and CNS Penetration in the RatJournal of Medicinal Chemistry, 2000
- Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990
- Drugs affecting dopamine neurons and yawning behaviorPharmacology Biochemistry and Behavior, 1977
- Is yawning a cholinergic response?Nature, 1977